How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials

被引：1

作者：

Intzes, Stergios ^{[1
]}

Symeonidou, Marianthi ^{[1
]}

Zagoridis, Konstantinos ^{[1
]}

Pentidou, Aikaterini ^{[1
]}

Bezirgianidou, Zoi ^{[1
]}

Papoutselis, Menelaos ^{[1
]}

Misidou, Christina ^{[1
]}

Roumpakis, Christoforos ^{[1
]}

Spanoudaki, Athina ^{[1
]}

Liapis, Konstantinos ^{[1
]}

Spanoudakis, Emmanouil ^{[1
]}

机构：

[1] Democritus Univ Thrace, Med Sch, Dept Hematol, Alexandroupolis 68100, PC, Greece

来源：

ANNALS OF HEMATOLOGY | 2024年 / 103卷 / 03期

关键词：

DLBCL; RCHOP; PFS; Novel agents; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PREVIOUSLY UNTREATED PATIENTS; DETUDES DES LYMPHOMES; PHASE-III TRIAL; R-CHOP; YOUNG-PATIENTS; OPEN-LABEL; INTENSIFIED CHEMOTHERAPY; DOXORUBICIN; VINCRISTINE;

D O I：

10.1007/s00277-023-05551-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

RCHOP is the standard of care for patients with diffuse large b-cell lymphoma (DLBCL) but failures occur in approximately 40% of them. We performed a meta-analysis of 21 randomized controlled trials (RCTs) comparing experimental regimens with RCHOP. We searched the database of PubMed with proper criteria, and data of efficacy (Progression Free Survival-PFS) in the ITT population were extracted and analyzed. Cross comparisons of RCTs were performed by using the CINEMA software. Odds ratio (OR) and 95% confidence intervals (95%, CI) are reported. The literature search yielded 21 RCTs including 5785 patients in the RCHOP arm and 5648 patients in the experimental arm. Odds ratio (OR) for PFS in the total cohort was OR (95%, CI): 0.87 (0.76-0.99), p=0.02. Among different strategies to improve RCHOP, addition of a novel agent on RCHOP improved PFS. In total 1740 patients in the RCHOP arm were compared with 1755 in the RCHOP plus a novel agent arm, and the OR (95% CI) for PFS was 0.84 (0.71-0.97), p=0.02. Indirect comparisons of nine studies adding a novel agent on RCHOP does not give prominence to any agent. Subgroup analysis according to cell of origin was performed for non-GC DLBCL patients. In this subgroup, 1546 patients treated with RCHOP were compared with 1538 patients treated with experimental regimens. The OR (95% CI) for PFS was 0.86 (0.73-1.02), p=0.34. Overall survival data extracted from 18 studies showed no superiority of experimental regimens over RCHOP. Efficacy of RCHOP backbone is marginally improved when adding a novel anti-lymphoma agent.

引用

页码：947 / 956

页数：10

共 39 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2] Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 [J].

Bartlett, Nancy L. ;

Wilson, Wyndham H. ;

Jung, Sin-Ho ;

Hsi, Eric D. ;

Maurer, Matthew J. ;

Pederson, Levi D. ;

Polley, Mei-Yin C. ;

Pitcher, Brandelyn N. ;

Cheson, Bruce D. ;

Kahl, Brad S. ;

Friedberg, Jonathan W. ;

Staudt, Louis M. ;

Wagner-Johnston, Nina D. ;

Blum, Kristie A. ;

Abramson, Jeremy S. ;

Reddy, Nishitha M. ;

Winter, Jane N. ;

Chang, Julie E. ;

Gopal, Ajay K. ;

Chadburn, Amy ;

Mathew, Susan ;

Fisher, Richard I. ;

Richards, Kristy L. ;

Schoder, Heiko ;

Zelenetz, Andrew D. ;

Leonard, John P. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (21) :1790-+

[3] Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials [J].

Castellino, A. ;

Chiappella, A. ;

LaPlant, B. R. ;

Pederson, L. D. ;

Gaidano, G. ;

Macon, W. R. ;

Inghirami, G. ;

Reeder, C. B. ;

Tucci, A. ;

King, R. L. ;

Congiu, A. ;

Foran, J. M. ;

Pavone, V. ;

Rivera, C. E. ;

Spina, M. ;

Ansell, S. M. ;

Cavallo, F. ;

Molinari, A. L. ;

Ciccone, Giovannino ;

Habermann, T. M. ;

Witzig, T. E. ;

Vitolo, U. ;

Nowakowski, G. S. .

BLOOD CANCER JOURNAL, 2018, 8

[4] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[5] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[6] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles [J].

Cunningham, David ;

Hawkes, Eliza A. ;

Jack, Andrew ;

Qian, Wendi ;

Smith, Paul ;

Mouncey, Paul ;

Pocock, Christopher ;

Ardeshna, Kirit M. ;

Radford, John A. ;

McMillan, Andrew ;

Davies, John ;

Turner, Deborah ;

Kruger, Anton ;

Johnson, Peter ;

Gambell, Joanna ;

Linch, David .

LANCET, 2013, 381 (9880) :1817-1826

[7] Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial [J].

Davies, Andrew ;

Cummin, Thomas E. ;

Barrans, Sharon ;

Maishman, Tom ;

Mamot, Christoph ;

Novak, Urban ;

Caddy, Josh ;

Stanton, Louise ;

Kazmi-Stokes, Shamim ;

McMillan, Andrew ;

Fields, Paul ;

Pocock, Christopher ;

Collins, Graham P. ;

Stephens, Richard ;

Cucco, Francesco ;

Clipson, Alexandra ;

Sha, Chulin ;

Tooze, Reuben ;

Care, Matthew A. ;

Griffiths, Gareth ;

Du, Ming-Qing ;

Westhead, David R. ;

Burton, Catherine ;

Johnson, Peter W. M. .

LANCET ONCOLOGY, 2019, 20 (05) :649-662

[8] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].

Dickinson, Michael J. ;

Carlo-Stella, Carmelo ;

Morschhauser, Franck ;

Bachy, Emmanuel ;

Corradini, Paolo ;

Iacoboni, Gloria ;

Khan, Cyrus ;

Wrobel, Tomasz ;

Offner, Fritz ;

Wu, Shang-Ju ;

Cartron, Guillaume ;

Hertzberg, Mark ;

Sureda, Anna ;

Perez-Callejo, David ;

Lundberg, Linda ;

Relf, James ;

Dixon, Mark ;

Clark, Emma ;

Humphrey, Kathryn ;

Hutchings, Martin ;

Trney, Marek .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24) :2220-2231

[9] Bias in meta-analysis detected by a simple, graphical test [J].

Egger, M ;

Smith, GD ;

Schneider, M ;

Minder, C .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634

[10] Epcoritamab: First Approval [J].

Frampton, James E. .

DRUGS, 2023, 83 (14) :1331-1340

← 1 2 3 4 →